The value of cancer care in low-resource settings
Dr Bishal Gyawali - Queen's University, Kingston, Canada
7 Feb 2020
Where have we got to with cancer treatment?
Prof Alexander Eggermont - Princess Máxima Center for Pediatric Oncology, Utrech...
27 Jan 2020
Immunotherapy for NSCLC: Recent advances and future directions
Prof Neal Ready - Duke University School of Medicine, Durham, USA
27 Jan 2020
Immunotherapy and targeted agents for elderly lung cancer patients
Dr Lore Decoster - University Hospital Brussels, Brussels, Belgium
28 Nov 2019
Challenges in treating elderly lung cancer patients
Prof Mike Jaklitsch - Harvard Medical School, Boston, USA
28 Nov 2019
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural m...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
7 Oct 2019
Checkmate 227: Final analysis for the non small cell lung cancer trial
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
4 Oct 2019
Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
4 Oct 2019
AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours
Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA
4 Oct 2019
Blood first assay screening in patients with ALK positive NSCLC
Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA
4 Oct 2019
Holistic management of patients with ALK-positive NSCLC
Rachel Thomas and Jackie Fenemore
3 Oct 2019
